non-invasive respiratory support (i.e. without endotracheal intubation) compared to supplemental oxygen is uncertain. Epinephrine or salbutamol (albuterol) have been suggested as a treatment option for transient tachypnea, as a result of evidence that β-agonists increase the speed of alveolar fluid clearance in the lung of newborns. However, the safety and effectiveness of these treatment approaches is not clear. Prognosis Transient tachypnea of the newborn is usually self limiting, however, it may be associated with wheezing syndromes as the child grows older. Epidemiology Transient tachypnea of the newborn occurs in approximately 1 in 100 preterm infants and 3.6-5.7 per 1000 term infants. It is most common in infants born by Caesarian section without a trial of labor after 35 weeks' gestation. Male infants and infants with an umbilical cord prolapse or perinatal asphyxia are at higher risk. Parental risk factors include use of pain control or anesthesia during labor, asthma, and diabetes. References External links Respiratory and cardiovascular disorders specific to the perinatal period Neonatology